Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 21;14(8):831.
doi: 10.3390/pathogens14080831.

Susceptibility of Neisseria gonorrhoeae to Zoliflodacin and Quinolones in Hyogo Prefecture, Japan

Takashi Yurube  1 , Katsumi Shigemura  2 , Yurino Kobayashi  3 , Taishi Maeda  3 , Nami Nishimura  3 , Ayaka Yamada  3 , Kotoko Kotani  3 , Saki Horii  3 , Hiroyuki Yoshida  4 , Kayo Osawa  3
Affiliations

Susceptibility of Neisseria gonorrhoeae to Zoliflodacin and Quinolones in Hyogo Prefecture, Japan

Takashi Yurube et al. Pathogens. .

Abstract

The DNA synthesis inhibitor zoliflodacin (ZFD) is expected to be effective against strains resistant to therapeutic agents for Neisseria gonorrhoeae infection. In addition to ZFD, we investigated the susceptibility of N. gonorrhoeae strains to ceftriaxone (CTRX), ciprofloxacin (CPFX), garenoxacin (GRNX), and sitafloxacin (STFX). Minimum inhibitory concentration values for ZFD and four other drugs were determined for 147 strains of N. gonorrhoeae isolated at medical institutions in Hyogo Prefecture, Japan, from 2015 to 2022. Amino acid alterations in gyrA, gyrB, parC, and parE were examined by polymerase chain reaction and sequencing analysis. Sequence type (ST) was determined for epidemiological analysis, and N. gonorrhoeae strains were classified. The non-susceptibility rate was not observed in CTRX. The lowest non-susceptibility rate was observed in ZFD (39.5%) compared to CPFX (80.3%), GRNX (83.7%), and STFX (65.3%) (all p < 0.0001). The most common amino acid alterations in gyrA and parC had non-susceptibility rates exceeding 80% to quinolones except ZFD, suggesting that these alterations may have influenced the resistance trend. STs were different between isolates in 2015 and those in 2020 and later. ZFD showed potent antimicrobial activity against N. gonorrhoeae strains that are highly resistant to quinolones. It may become a new option in the treatment of gonococcal infections.

Keywords: DNA gyrase; Neisseria gonorrhoeae; quinolones; susceptibility; topoisomerase IV; zoliflodacin (ZFD).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Annual trends of non-susceptibility rates of 147 N. gonorrhoeae strains to antibiotics. The results of the antimicrobial susceptibility testing of ciprofloxacin (CPFX) (a), garenoxacin (GRNX) (b), sitafloxacin (STFX) (c), and zoliflodacin (ZFD) (d) in N. gonorrhoeae strains show the rates of resistant (R) and intermediate (I) strains. All annual trends for the non-sensitivity rates were examined by the chi-square test, and each annual trend was compared among the 2015 and other years’ strains by the Bonferroni method adjustment (p < 0.0083 with a significant difference).
See this image and copyright information in PMC

References

    1. Gonorrhoa (Neisseria gonorrhoeae) [(accessed on 4 December 2024)]. Available online: https://www.who.int/news-room/fact-sheets/detail/gonorrhoea-(neisseria-g...
    1. Marshall H.S., Molina J.M., Berlaimont V., Mulgirigama A., Sohn W.Y., Berçot B., Bobde S. Eur Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends. J. Clin. Microbiol. Infect. Dis. 2025;44:233–250. doi: 10.1007/s10096-024-04968-8. - DOI - PMC - PubMed
    1. Unemo M., Del Rio C., Shafer W.M. Antimicrobial resistance expressed by Neisseria gonorrhoeae: A major global public health problem in the 21st Century. Microbiol. Spectr. 2016;10:213–237. doi: 10.1128/microbiolspec.EI10-0009-2015. - DOI - PMC - PubMed
    1. Unemo U. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J. Antimicrob. Chemother. 2021;76:1221–1228. doi: 10.1093/jac/dkab024. - DOI - PubMed
    1. Alm R.A., Lahiri S.D., Kutschke A., Otterson L.G., McLaughlin R.E., Whiteaker J.D., Lewis L.A., Su X., Huband M.D., Gardner H., et al. Characterization of the novel DNA gyrase inhibitor AZD0914: Low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 2015;59:1478–1486. doi: 10.1128/AAC.04456-14. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources